Loading...
Loading...
FATE| Name | Value |
|---|---|
| Revenues | 1.9M |
| Cost of Revenue | 0.0M |
| Gross Profit | 1.9M |
| Operating Expense | 63.6M |
| Operating I/L | -61.7M |
| Other Income/Expense | 9.6M |
| Interest Income | 3.9M |
| Pretax | -52.2M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -52.2M |
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's portfolio includes NK- and T-cell immuno-oncology programs such as FT516, FT596, FT538, FT576, FT819, FT536, and FT500, targeting various forms of leukemia, lymphoma, and solid tumors. Fate Therapeutics generates revenue through the development and commercialization of off-the-shelf iPSC-derived CAR T-cell product candidates, strategic research collaborations, and license agreements with pharmaceutical companies to enhance the therapeutic properties of genetically-engineered T-cell immunotherapies.
